NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
IYUZEH (latanoprost ophthalmic solution 0.005%) by Thea Pharma. Approved for prostaglandin analog [epc]. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IYUZEH is a prostaglandin analog ophthalmic solution approved in December 2022 for treating ocular hypertension and open-angle glaucoma. It works by increasing aqueous humor outflow through the eye's drainage pathways to lower intraocular pressure. This is a branded generic entry into a mature, well-established therapeutic class.
$0.252MPart D
Peak5.2 years to LOEEarly-stage peak lifecycle product with minimal current utilization suggests limited team headcount; career growth depends on market penetration strategy and competitive positioning.
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IYUZEH represents a commercial-stage branded generic in a mature, competitive market with minimal linked job activity, suggesting Thea Pharma maintains a lean commercial footprint for this product. Opportunities are concentrated in field sales, managed care contracting, and pharmacy network development rather than clinical or discovery roles.
Company
Worked on IYUZEH at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.